ReviewEuropean respiratory review : an official journal of the European Respiratory Society2016
Practical considerations for therapies targeting the prostacyclin pathway.
Review in European respiratory review : an official journal of the European Respiratory Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Food Effects on the Pharmacokinetics of Single Dose and Steady-State Ralinepag, a Novel Oral Prostacyclin Agonist, in Healthy Volunteers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Practical Considerations for Managing Patients on Tyvaso DPI (Treprostinil Inhalation Powder).Pulmonary circulation · 2025Review
- Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2024Review
- Impact of selexipag maintenance dose on persistence, adherence, and hospitalization in US patients with pulmonary arterial hypertension.Pulmonary circulation · 2024Article
- Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date.Drug, healthcare and patient safety · 2024Review
- Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.Journal of patient-reported outcomes · 2023Article
- Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future.Pharmaceuticals (Basel, Switzerland) · 2023Review
- INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).Pulmonary circulation · 2022Article
- Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?American journal of respiratory and critical care medicine · 2022Article
- BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.Pulmonary circulation · 2022Article
- Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.Journal of health economics and outcomes research · 2022Article
- Article
- Real-world experience of selexipag titration in pulmonary arterial hypertension.The British journal of cardiology · 2021Article
- Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report.European heart journal. Case reports · 2020Article
- Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2019Article
- Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy.African journal of thoracic and critical care medicine · 2019Review
- Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.British journal of pharmacology · 2018Article
- Pulmonary arterial hypertension: tailoring treatment to risk in the current era.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Patient engagement and self-management in pulmonary arterial hypertension.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- The revolution of pulmonary arterial hypertension.European respiratory review : an official journal of the European Respiratory Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapies that target the prostacyclin pathway play a key role in the treatment of both early- and late-stage pulmonary arterial hypertension, and provide significant clinical benefits for patients. A number of agents have been approved, which are administered via intravenous, subcutaneous, inhaled or oral routes. The use of these therapies is associated with practical challenges, relating to the need for up-titration and their routes of administration. We discuss here a number of measures that can be taken to support patients and healthcare professionals in order to address the complexities of using these therapies and to encourage compliance. Providing patients with timely information and education, together with practical advice on managing their medication and associated equipment, assists patients with day-to-day management of therapy. Referral to patient associations and support groups can be of further benefit. With an effective management plan and an experienced multidisciplinary team, the use of therapies that target the prostacyclin pathway can be optimised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.